Cargando…

Prevalence of Nephrotoxicity in HIV Patients Treated with Tenofovir Disoproxil Fumarate: A Single-center Observational Study

OBJECTIVES: Tenofovir disoproxil fumarate (TDF) has been reported to cause nephrotoxicity necessitating cessation in some patients. No information is available on the nephrotoxic effect of TDF in Omani or regional patients with HIV infection. We sought to determine the prevalence of the nephrotoxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Kowthar Salman, Balkhair, Abdullah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OMJ 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505346/
https://www.ncbi.nlm.nih.gov/pubmed/31110631
http://dx.doi.org/10.5001/omj.2019.44
_version_ 1783416748742017024
author Hassan, Kowthar Salman
Balkhair, Abdullah
author_facet Hassan, Kowthar Salman
Balkhair, Abdullah
author_sort Hassan, Kowthar Salman
collection PubMed
description OBJECTIVES: Tenofovir disoproxil fumarate (TDF) has been reported to cause nephrotoxicity necessitating cessation in some patients. No information is available on the nephrotoxic effect of TDF in Omani or regional patients with HIV infection. We sought to determine the prevalence of the nephrotoxic effects of TDF in our cohort of Omani patients with HIV and investigate the nephrotoxic effects of other cofactors. METHODS: We conducted an observational cohort study on 83 Omani patients currently on TDF-containing antiretroviral therapy. Renal dysfunction was monitored by measuring the serum creatinine estimated glomerular function rate (eGFR), urinary protein creatinine ratio (uPCR), and fractional excretion of phosphate (FEPi). Fisher’s exact test was used to determine any additional nephrotoxic effects of cofactors. RESULTS: The median values for the duration of TDF use, patient age, and body mass index (BMI) at the time of the study were 178 weeks (range = 3–554), 42 years (range = 21–80), and 27 (range = 17.4–42.7), respectively. The median initial CD4 count and viral load were 205 × 10(6)/L (range = 3–1745) and 37 250 copies/mL (range = undetectable–9 523 428), respectively. FEPi was high in two (2.4%) patients, moderate in 26 (31.3%), and low in 55 (66.3%) patients. uPCR was high in 10 (12.0%) patients, moderate in 28 (33.7%), and low in 45 (54.2%) patients. No cofactors added to the nephrotoxicity except hypertension (p = 0.045). CONCLUSIONS: Better definitions for TDF-associated toxicity are needed. uPCR is not a very good indicator of TDF-associated tubular dysfunction. Omani patients with HIV on TDF have a 4% prevalence of renal toxicity, but a study with a larger number of patients is required to explore this observation further. Cofactors like duration of TDF use, age, BMI, gender, diabetes mellitus, and use of protease inhibitors did not have an impact on the severity of FEPi and uPCR.
format Online
Article
Text
id pubmed-6505346
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher OMJ
record_format MEDLINE/PubMed
spelling pubmed-65053462019-05-20 Prevalence of Nephrotoxicity in HIV Patients Treated with Tenofovir Disoproxil Fumarate: A Single-center Observational Study Hassan, Kowthar Salman Balkhair, Abdullah Oman Med J Original Article OBJECTIVES: Tenofovir disoproxil fumarate (TDF) has been reported to cause nephrotoxicity necessitating cessation in some patients. No information is available on the nephrotoxic effect of TDF in Omani or regional patients with HIV infection. We sought to determine the prevalence of the nephrotoxic effects of TDF in our cohort of Omani patients with HIV and investigate the nephrotoxic effects of other cofactors. METHODS: We conducted an observational cohort study on 83 Omani patients currently on TDF-containing antiretroviral therapy. Renal dysfunction was monitored by measuring the serum creatinine estimated glomerular function rate (eGFR), urinary protein creatinine ratio (uPCR), and fractional excretion of phosphate (FEPi). Fisher’s exact test was used to determine any additional nephrotoxic effects of cofactors. RESULTS: The median values for the duration of TDF use, patient age, and body mass index (BMI) at the time of the study were 178 weeks (range = 3–554), 42 years (range = 21–80), and 27 (range = 17.4–42.7), respectively. The median initial CD4 count and viral load were 205 × 10(6)/L (range = 3–1745) and 37 250 copies/mL (range = undetectable–9 523 428), respectively. FEPi was high in two (2.4%) patients, moderate in 26 (31.3%), and low in 55 (66.3%) patients. uPCR was high in 10 (12.0%) patients, moderate in 28 (33.7%), and low in 45 (54.2%) patients. No cofactors added to the nephrotoxicity except hypertension (p = 0.045). CONCLUSIONS: Better definitions for TDF-associated toxicity are needed. uPCR is not a very good indicator of TDF-associated tubular dysfunction. Omani patients with HIV on TDF have a 4% prevalence of renal toxicity, but a study with a larger number of patients is required to explore this observation further. Cofactors like duration of TDF use, age, BMI, gender, diabetes mellitus, and use of protease inhibitors did not have an impact on the severity of FEPi and uPCR. OMJ 2019-05 /pmc/articles/PMC6505346/ /pubmed/31110631 http://dx.doi.org/10.5001/omj.2019.44 Text en The OMJ is Published Bimonthly and Copyrighted 2019 by the OMSB. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). ( https://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle Original Article
Hassan, Kowthar Salman
Balkhair, Abdullah
Prevalence of Nephrotoxicity in HIV Patients Treated with Tenofovir Disoproxil Fumarate: A Single-center Observational Study
title Prevalence of Nephrotoxicity in HIV Patients Treated with Tenofovir Disoproxil Fumarate: A Single-center Observational Study
title_full Prevalence of Nephrotoxicity in HIV Patients Treated with Tenofovir Disoproxil Fumarate: A Single-center Observational Study
title_fullStr Prevalence of Nephrotoxicity in HIV Patients Treated with Tenofovir Disoproxil Fumarate: A Single-center Observational Study
title_full_unstemmed Prevalence of Nephrotoxicity in HIV Patients Treated with Tenofovir Disoproxil Fumarate: A Single-center Observational Study
title_short Prevalence of Nephrotoxicity in HIV Patients Treated with Tenofovir Disoproxil Fumarate: A Single-center Observational Study
title_sort prevalence of nephrotoxicity in hiv patients treated with tenofovir disoproxil fumarate: a single-center observational study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505346/
https://www.ncbi.nlm.nih.gov/pubmed/31110631
http://dx.doi.org/10.5001/omj.2019.44
work_keys_str_mv AT hassankowtharsalman prevalenceofnephrotoxicityinhivpatientstreatedwithtenofovirdisoproxilfumarateasinglecenterobservationalstudy
AT balkhairabdullah prevalenceofnephrotoxicityinhivpatientstreatedwithtenofovirdisoproxilfumarateasinglecenterobservationalstudy